no longer losing weight on tirzepatide Tirzepatide: A Breakthrough Approach to Safely Why Tirzepatide Isn't Working: 2026

Your pharmacy sends a 20 mg/mL vial for your next refill

Draw up to exactly the calculated mark with the insulin syringe

The best non-diabetic body-composition anchor favors tirzepatide, about 75:25 fat-to-lean loss in its DXA data versus about 62:38 in semaglutides. This is cross-trial evidence, not a head-to-head maintenance-dose DXA result

Insulin secretion from beta cells within intact islets: Location matters

Patients with specific FTO or MC4R variants often benefit from earlier consideration of tirzepatide's dual-receptor approach

People with a history of pancreatitis should use tirzepatide only under careful supervision, and people with diabetes need monitoring given the combined glucose effects